Klinikum Chemnitz gGmbH
- Address
- Bürgerstrasse 2, 09113 Chemnitz, Germany
Hemic and Lymphatic Diseases
The Onkologisches Centrum Chemnitz at Klinikum Chemnitz gGmbH is conducting studies on Acute Myeloid Leukemia, aiming to define safety, tolerability and optimal dosing of emerging agents for patients with refractory disease.
- Safety and tolerability assessment in relapsed/refractory patients
- Determination of dose‑limiting toxicities and recommended expansion dose
- Exploration of novel therapeutic strategies to improve outcomes
These efforts support the site’s commitment to advancing care for hematologic malignancies in the Chemnitz region.
Neoplasms
Research at the center includes a neoadjuvant trial for triple‑negative early breast cancer with low recurrence risk, comparing sacituzumab govitecan alone versus its combination with pembrolizumab to increase pathologic complete response and long‑term disease‑free survival.
- Evaluation of combination immunotherapy in early‑stage disease
- Measurement of pathologic complete response rates
- Monitoring three‑year invasive disease‑free survival outcomes
The study reflects the site’s focus on innovative oncology treatments for breast cancer patients in Europe.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Ab Science1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Klinikum Chemnitz gGmbH
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Comparative Study of Sacituzumab Govitecan Versus Sacituzumab Govitecan Plus Pembrolizumab in Low-Risk Triple-Negative Early Breast Cancer | WSG Westdeutsche Studiengruppe GmbH | Phase II | Recruiting | Oct 2024 | — |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| 1-{4-[2-(5-Ethoxymethyl-2-Methyl-Phenylamino)-Oxazol-5-Yl]-Phenyl}-Imidazolidin-2-One | 1 | Unknown | 2024-12-02 | 2024-12-02 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.